These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 19835953)

  • 1. Effects of rosiglitazone on intramyocellular lipid accumulation in Psammomys obesus.
    Molero JC; Lee S; Leizerman I; Chajut A; Cooper A; Walder K
    Biochim Biophys Acta; 2010 Feb; 1802(2):235-9. PubMed ID: 19835953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scanning electron microscopic analysis of intramyocellular lipid droplets in an animal model of type 2 diabetes.
    Fraenkel M; Weiss R; Leizerman I; Anaby D; Golomb E; Leibowitz G; Kaiser N
    Obesity (Silver Spring); 2008 Mar; 16(3):695-9. PubMed ID: 18239599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
    Kim HJ; Jung TW; Kang ES; Kim DJ; Ahn CW; Lee KW; Lee HC; Cha BS
    Metabolism; 2007 May; 56(5):676-85. PubMed ID: 17445544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of nutritionally induced diabetes by rosiglitazone in the gerbil Psammomys obesus.
    Hefetz S; Ziv E; Jörns A; Lenzen S; Shafrir E
    Diabetes Metab Res Rev; 2006; 22(2):139-45. PubMed ID: 16088969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
    Brunani A; Caumo A; Graci S; Castagna G; Viberti G; Liuzzi A
    Diabetes Obes Metab; 2008 Jun; 10(6):460-7. PubMed ID: 17394563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.
    Jucker BM; Schaeffer TR; Haimbach RE; Mayer ME; Ohlstein DH; Smith SA; Cobitz AR; Sarkar SK
    Metabolism; 2003 Feb; 52(2):218-25. PubMed ID: 12601636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of metabolic effects of rosiglitazone.
    Seda O; Sedová L; Oliyarnyk O; Kazdová L; Krenová D; Corbeil G; Hamet P; Tremblay J; Kren V
    Pharmacogenomics; 2008 Feb; 9(2):141-55. PubMed ID: 18370844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1 alpha and PPAR beta/delta gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus.
    Mensink M; Hesselink MK; Russell AP; Schaart G; Sels JP; Schrauwen P
    Int J Obes (Lond); 2007 Aug; 31(8):1302-10. PubMed ID: 17310221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
    Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of lipogenesis in the development of obesity and diabetes in Israeli sand rats (Psammomys obesus).
    Lewandowski PA; Cameron-Smith D; Jackson CJ; Kultys ER; Collier GR
    J Nutr; 1998 Nov; 128(11):1984-8. PubMed ID: 9808653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
    Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
    Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between visceral adiposity and intramyocellular lipid content in two rat models of insulin resistance.
    Korach-André M; Gao J; Gounarides JS; Deacon R; Islam A; Laurent D
    Am J Physiol Endocrinol Metab; 2005 Jan; 288(1):E106-16. PubMed ID: 15328072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of muscle malonyl-CoA levels in the nutritionally insulin-resistant desert gerbil, Psammomys obesus.
    Shafrir E; Ziv E; Saha AK; Ruderman NB
    Diabetes Metab Res Rev; 2002; 18(3):217-23. PubMed ID: 12112940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
    Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
    Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eicosapentaenoic acid modulates fatty acid metabolism and inflammation in Psammomys obesus.
    Atek-Mebarki F; Hichami A; Abdoul-Azize S; Bitam A; Koceïr EA; Khan NA
    Biochimie; 2015 Feb; 109():60-6. PubMed ID: 25528298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipocyte differentiation-related protein and OXPAT in rat and human skeletal muscle: involvement in lipid accumulation and type 2 diabetes mellitus.
    Minnaard R; Schrauwen P; Schaart G; Jorgensen JA; Lenaers E; Mensink M; Hesselink MK
    J Clin Endocrinol Metab; 2009 Oct; 94(10):4077-85. PubMed ID: 19602560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin resistance in a polygenic, hyperleptinemic animal model of obesity and NIDDM: Psammomys obesus.
    Walder K; Lewandowski P; Morton G; Sanigorski A; de Silva A; Zimmet P; Collier GR
    Int J Obes Relat Metab Disord; 1999 Jan; 23(1):83-9. PubMed ID: 10094582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calpain 3 gene expression in skeletal muscle is associated with body fat content and measures of insulin resistance.
    Walder K; McMillan J; Lapsys N; Kriketos A; Trevaskis J; Civitarese A; Southon A; Zimmet P; Collier G
    Int J Obes Relat Metab Disord; 2002 Apr; 26(4):442-9. PubMed ID: 12075569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
    Vedtofte L; Bodvarsdottir TB; Gotfredsen CF; Karlsen AE; Knudsen LB; Heller RS
    Regul Pept; 2010 Feb; 160(1-3):106-14. PubMed ID: 20005262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.